HF Advisory Group LLC Acquires 990 Shares of GSK plc (NYSE:GSK)

HF Advisory Group LLC grew its holdings in shares of GSK plc (NYSE:GSK) by 12.8% in the fourth quarter, HoldingsChannel reports. The fund owned 8,743 shares of the pharmaceutical company’s stock after purchasing an additional 990 shares during the quarter. HF Advisory Group LLC’s holdings in GSK were worth $296,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of GSK. Eastern Bank purchased a new position in GSK during the third quarter valued at approximately $26,000. ST Germain D J Co. Inc. raised its position in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the period. Sunbelt Securities Inc. lifted its stake in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares in the last quarter. Concord Wealth Partners increased its stake in GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares in the last quarter. Finally, Fortitude Family Office LLC bought a new stake in GSK during the third quarter valued at about $42,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Up 0.0 %

Shares of GSK opened at $33.46 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock has a market capitalization of $69.34 billion, a price-to-earnings ratio of 21.72, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The business’s 50 day simple moving average is $34.02 and its 200-day simple moving average is $37.98.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were paid a dividend of $0.3928 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a yield of 4.70%. GSK’s dividend payout ratio is presently 96.10%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on GSK shares. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 13th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.